Please note: ASGCT has come to the conclusion that it is only possible to fulfill the Society's mission by hosting the 23rd Annual Meeting virtually. More information is available here.
New for 2020, ASGCT is changing the Pre-Meeting Workshop program to offer more half-day sessions. Official schedules to follow in the coming weeks. All Pre-Meeting Workshops will take place Monday, May 11, 2020. Each workshop has an individual registration rate, and attendees may register for any or all workshops independent of, or in addition to, registration for the Annual Meeting.
More details about the Pre-Meeting Workshops are available in the meeting app.
|
|
||
| Members | $100 | |
| Transitional Members | $100 | |
| Associate Members | $25 | |
| Nonmembers | $200 | |
| Non-member Grad Students | $50 | |
The CAR T and Related Immune Effector Cell Therapies Workshop will feature discussions of the current state of CAR T therapeutic approaches in light of recent FDA approvals with updates on clinical long term follow-up gene editing and going beyond autologous CAR-T cells for cancer.
View CAR T and Immune Effector Cell Therapies Syllabus
The Clinical Trials Training workshop I will address the development of early stage clinical trials, specifically covering the journey from preclinical development to clinical trial implementation and is intended primarily for early stage investigators.
View Clinical Trials Training I Syllabus
The Commercialization workshop I will focus on the regulatory pathways to the commercialization of gene and cell therapy products with discussions covering the harmonization of global regulatory approaches.
View Commercialization I Syllabus
The Stem Cell Therapies workshop will feature a diverse offering of presentations covering a broad array of topics in stem cell therapies, including scientific advances and clinical applications.
View Stem Cell Therapies Syllabus
The Clinical Trials Training workshop II will provide an in-depth discussion, including case studies and first-hand accounts, of the development and launch of gene therapy clinical trials, both in academia and in commercial settings.
View Clinical Trials Training II Syllabus
The Commercialization workshop II will focus on the unique challenges emerging technologies pose in designing acceptable business models to maximize patient access and discussions of value based pricing and reimbursement for gene therapies.
View Commercialization II - Value, Evidence, and Reimbursement Syllabus
The Gene Editing workshop will provide an overview of current gene editing technologies and approaches, emerging uses and applications, with sessions highlighting junior investigators and clinical gene editing programs.
The Oncolytic Viruses workshop will feature overviews of the recent advances in oncolytics, including oncolytic viruses, cancer vaccines, and novel combination immuno-oncologic therapies.
View Oncolytic Viruses Syllabus
The Viral Vector Development workshop will provide an in-depth discussion of the advances as well as the challenges in vector development and manufacturing, including GMP production.
View Viral Vector Development Syllabus
Abstract Notifications Sent
April 6, 2020
Abstracts Released
April 28, 2020
23rd ASGCT Annual Meeting
May 12 – 15, 2020
Use the ASGCT app on your mobile device to build your schedule, read the abstracts (released on April 28), and guide your way through the Hynes Convention Center.
Hynes Convention Center
900 Boylston St.
Boston, MA 02115
